Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists
Thomas Berger(Medical University of Vienna), Celia Oreja‐Guevara, Maura Pugliatti(University of Sassari), Patrick Vermersch(Université de Lille), Veronica Popescu(Hasselt University), Laura Airas(Turku University Hospital), Markus Zeitlinger(Medical University of Vienna), Mona Alkhawajah(Alfaisal University), Carlo Pozzilli(Ophthalmology Clinic), Jelena Drulović(University of Belgrade), Melinda Magyari(University of Copenhagen), Bart Van Wijmeersch(Hasselt University), Magd Zakaria(Ain Shams University)
Cited by 4
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.
|Journal of Neurology Neurosurgery & Psychiatry|1992|1.8k
Cost of disorders of the brain in Europe 2010
|European Neuropsychopharmacology|2011|1.7k
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
|Intensive Care Medicine|2020|1.1k
A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging
|Journal of the Neurological Sciences|1993|930